Stimulatory as well as inhibitory effects of ethinyloestradiol on the metabolic clearances of propranolol in young women

British Journal of Clinical Pharmacology

Volumn 41, Issue 4, 1996, Pages 305-309

  Walle, T ^a   Fagan, T C ^b   Walle, U K ^a   Topmiller, M J ^b  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

Author keywords

Contraceptives; Ethinyloestradiol; Metabolism; Oral; Propranolol; Women

Indexed keywords

ETHINYLESTRADIOL; NORETHISTERONE; PROPRANOLOL;

ADULT; AREA UNDER THE CURVE; ARTICLE; DRUG ANTAGONISM; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG CONJUGATION; DRUG GLUCURONIDATION; DRUG METABOLISM; DRUG POTENTIATION; FEMALE; HUMAN; HUMAN EXPERIMENT; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL;

EID: 0029915667     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2125.1996.03097.x     Document Type: Article

References (27)

1. Kato R. Sex-related differences in drug metabolism. Drug Metab Dispos 1974; 3: 1-32.
2. Bonate PL. Gender-related differences in xenobiotic metabolism. J Clin Pharmacol 1991; 31: 684-90.
3. Walle T, Walle UK, Cowart TD, Conradi EC. Pathway-selective sex differences in the metabolic clearance of propranolol in human subjects. Clin Pharmacol Ther 1989; 46: 257-63.
4. Walle T, Walle UK, Mathur RS, Palesch YY, Conradi EC. Propranolol metabolism in normal subjects: association with sex steroid hormones. Clin Pharmacol Ther 1994; 56: 127-132.
5. Topmiller MJ, Walle T, Fagan TC, Walle UK, Pearson J, Mathur RS. The menstrual cycle does not affect propranolol metabolism. Clin Pharmacol Ther 1993; 53: 187.
6. Walle UK, Fagan TC, Topmiller MJ, Conradi EC, Walle T. The influence of gender and sex steroid hormones on the plasma binding of propranolol enantiomers. Br J Clin Pharmacol 1994; 37: 21-25.
7. Walle T, Walle UK, Olanoff LS, Conradi EC. Partial metabolic clearances as determinants of the oral bioavailability of propranolol. Br J Clin Pharmacol 1986; 22: 317-323.
8. Hassard TH. Understanding Biostatistics, Mosby - Year Book, Inc., St. Louis, MO, 1991.
9. Stoer GP, Kroboth PD, Juhl RP, Wender DB, Phillips JP, Smith RB. Effect of oral contraceptives on triazolam, temazepam, alprazolam, and lorazepam kinetics. Clin Pharmacol Ther 1984; 36: 683-690.
10. Roberts RK, Grice J, McGuffie C, Heilbronn L. Oral contraceptive steroids impair the elimination of theophylline. J Lab Clin Med 1983; 101: 821-825.
11. Abernethy DR, Todd EL. Impairment of caffeine clearance by chronic use of low-dose oestrogen-containing oral contraceptives. Eur J Clin Pharmacol 1985; 28: 425-428.
12. Luoma PV, Heikkinen JE, Ehnholm C, Ylöstalo PR. One year study of effects of an oestrogen-dominant oral contraceptive on serum high-density lipoprotein cholesterol, apolipoproteins A-I and A-II and hepatic microsomal function. Eur J Clin Pharmacol 1987; 31: 563-567.
13. Deray G, Le Hoang P, Cacoub P, Assogba U, Grippon P, Baumelou A. Oral contraceptive interaction with cyclosporin. Lancet 1987; i: 158-159.
14. Walle T, Walle UK, Cowart TD, Conradi EC, Gaffney TE. Selective induction of propranolol metabolism by smoking; additional effects on renal clearance of metabolites. J Pharmacol Exp Ther 1987; 241: 928-933.
15. Steiner A, Walle UK, Walle T. Induction of propranolol metabolism in the Hep G2 human hepatoma cell line. J Pharm Pharmacol 1992; 44: 611-614.
16. Fujita S, Umeda S, Funae Y, et al. Regio- and stereoselective propranolol metabolism by 15 forms of purified cytochromes P-450 from rat liver. J Pharmacol Exp Ther 1993; 264: 226-233.
17. Yoshimoto K, Echizen H, Chiba K, Tani M, Ishizaki T. Identification of human CYP isoforms involved in the metabolism of propranolol enantiomers - N-desisopropylation is mediated mainly by CYP1A2. Br J Clin Pharmacol 1995; 39: 421-431.
18. Ward SA, Walle T, Walle UK, Wilkinson GR, Branch RA. Propranolol's metabolism is determined by both mephenytoin and debrisoquin hydroxylase activities. Clin Pharmacol Ther 1989; 45: 72-79.
19. Guengerich FP. Oxidation of 17α-ethynylestradiol by human liver cytochrome P-450. Mol Pharmacol 1988; 33: 500-508.
20. Mitchell MC, Hanew T, Meredith CG, Schenker S. Effects of oral contraceptive steroids on acetaminophen metabolism and elimination. Clin Pharmacol Ther 1983; 34: 48-53.
21. Miners JO, Robson RA, Birkett DJ. Gender and oral contraceptive steroids as determinants of drug glucuronidation: effects of clofibric acid elimination. Br J Clin Pharmacol 1984; 18: 240-243.
22. Watson KJR, Ghabrial H, Mashford ML, Harman PJ, Breen KJ, Desmond PV. The oral contraceptive pill increases morphine clearance but does not increase hepatic blood flow. Gastroenterology 1986; 90: 1779 (abstract).
23. Lennard MD, Jackson PR, Freestone S, Tucker GT, Ramsay LE, Woods HF. The relationship between debrisoquin oxidation phenotype and the pharmacokinetics and pharmacodynamics of propranolol. Br J Clin Pharmacol 1984; 17: 679-685.
24. Raghuram TC, Koshakji RP, Wilkinson GR, Wood AJJ. Polymorphic ability to metabolize propranolol alters 4-hydroxypropranolol levels, but not beta blockade. Clin Pharmacol Ther 1984; 36: 51-56.
25. Prueksaritanont T, Correia MA, Rettie AE, Swinney DC, Thomas PE, Benet LZ. Cyclosporine metabolism by rat liver microsomes. Evidence for involvement of enzyme(s) other than cytochromes P-450 3A. Drug Metab Dispos 1993; 21: 730-737.
26. White INH, Muller-Eberhard U. Decreased liver cytochrome P-450 in rats caused by norethindrone or ethynyloestradiol. Biochem J 1977; 166: 57-64.
27. Field B, Lu C, Hepner GW. Inhibition of hepatic drug metabolism by norethindrone. Clin Pharmacol Ther 1979; 25: 196-198.